# Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI

> **NCT02301910** · PHASE3 · COMPLETED · sponsor: **Supergene, LLC** · enrollment: 382 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Recombinant staphylokinase
- **DRUG:** Tenecteplase

## Key facts

- **NCT ID:** NCT02301910
- **Lead sponsor:** Supergene, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-16
- **Primary completion:** 2016-12-01
- **Final completion:** 2016-12-01
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02301910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02301910, "Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02301910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*